SAM
ZBIO

SEB Asset Management’s Zenas BioPharma ZBIO Stock Holding History

SEB Asset Management’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-163,860
Closed -$3.2M – 739
2026
Q1 		$3.2M Buy
+163,860
New +$3.68M 0.01% 526

Other funds holding ZBIO

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SEB Asset Management's ZBIO Position: Q2 2026 in Review

SEB Asset Management sold out of Zenas BioPharma (ZBIO) in Q2 2026, closing a stake of 163,860 shares — an estimated $3.2M sold.

SEB Asset Management first reported a position in ZBIO in Q1 2026 and held it in 1 quarter. The position peaked at $3.2M in Q1 2026. 132 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • SEB Asset Management reported no remaining Zenas BioPharma position as of Q2 2026 after selling out during the quarter.
  • SEB Asset Management sold 163,860 Zenas BioPharma shares in Q2 2026, an estimated $3.2M.
  • SEB Asset Management first reported a position in Zenas BioPharma in Q1 2026 and held it in 1 quarter.
  • SEB Asset Management's Zenas BioPharma position peaked at $3.2M in Q1 2026.
  • 132 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on SEB Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.